簡要描述:巨噬細(xì)胞炎性蛋白3樣蛋白1抗體免 疫 原;KLH conjugated synthetic peptide derived from human LD78 beta/CCL3L1: 31-93/93
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
巨噬細(xì)胞炎性蛋白3樣蛋白1抗體
產(chǎn)品名稱 | 英文名稱 | 貨號(hào) |
巨噬細(xì)胞炎性蛋白3樣蛋白1抗體 | LD78 beta/CCL3L1 | GOY-01K2597 |
商品屬性:
英文名稱: LD78 beta/CCL3L1
中文名:巨噬細(xì)胞炎性蛋白3樣蛋白1抗體
別 名;464.2; C C motif
chemokine 3 like 1; CCL3L1; CCL3L3; Chemokine (C C motif) ligand 3 like 1;
Chemokine (C C motif) ligand 3 like 3; Chemokine (C C motif) ligand 3 like,
centromeric; chemokine (CC motif) ligand 3 like 1; CL3L1_HUMAN; D17S1718; G0/G1
switch regulatory protein 19-2; G0S19-2; LD78; LD78 beta(1-70); LD78-beta(1-70);
LD78-beta(5-70); LD78BETA; MGC104178; MGC12815; MGC182017; MIP1AP; PAT 464.2;
SCYA3L; SCYA3L1; Small inducible cytokine A3 like 1 precursor; Small-inducible
cytokine A3-like 1; Tonsillar lymphocyte LD78 beta; Tonsillar lymphocyte LD78
beta protein.
研究領(lǐng)域;細(xì)胞生物 免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo)
抗體來源;Rabbit
克隆類型;Polyclonal
交叉反應(yīng);(predicted:
Human, )
產(chǎn)品應(yīng)用;IHC-P=1:100-500
IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;8kDa
細(xì)胞定位;分泌型蛋白
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH
conjugated synthetic peptide derived from human LD78 beta/CCL3L1: 31-93/93
亞 型;IgG
純化方法;affinity
purified by Protein A
緩 沖 液;0.01M
TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng);This
product as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
This gene is one of several cytokine genes that
are clustered on the q-arm of chromosome 17. Cytokines are a family of secreted
proteins that function in inflammatory and immunoregulatory processes. The
protein encoded by this gene binds to several chemokine receptors, including
chemokine binding protein 2 and chemokine (C-C motif) receptor 5 (CCR5). CCR5
is a co-receptor for HIV, and binding of this protein to CCR5 inhibits HIV
entry. The copy number of this gene varies among individuals, where most
individuals have one to six copies, and a minority of individuals have zero
or more than six copies. There are conflicting reports about copy number
variation of this gene and its correlation to disease
susceptibility.[provided by RefSeq, Apr 2014] Chemotactic for lymphocytes and monocytes. Is a
ligand for CCR1, CCR3 and CCR5. Is an inhibitor of HIV-1-infection. The
processed form LD78-beta(3-70) shows a 20-fold to 30-fold higher chemotactic
activity and is a very potent inhibitor of HIV-1-infection. LD78-beta(3-70)
is also a ligand for CCR1, CCR3 and CCR5. |
多克隆抗體制備:
我公司合成抗原,保證陽性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測結(jié)果是陽性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
鼠單克隆抗體制備:
客戶可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專業(yè)的建議。在制備過程中,與客戶互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽性血清檢測達(dá)到合同要求的同時(shí),也能滿足客戶抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無法做到的。我公司已搭建好的抗體測序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶提供各種類型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測服務(wù):
我公司也為客戶提供單項(xiàng)免疫學(xué)和檢測服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測服務(wù)。
抗體定制服務(wù):
已注冊商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測試的客戶量身定制的專業(yè)服務(wù),主要面向工業(yè)客戶。
產(chǎn)品咨詢
歡迎您關(guān)注我們的微信了解更多信息
電話
微信掃一掃